Document:

Exhibit
10.14

 

Execution
Copy

 

Private
Placement Agreement

 

THIS
PRIVATE PLACEMENT AGREEMENT
(the “Agreement”)
is made and entered into as of the 13th day of February, 2017 (the “Execution Date”), by and among Therapix
Biosciences Ltd., a company organized under the laws of the State of Israel having its principal offices at Azrieli Center
(Square Tower) 27th Fl., Tel Aviv Israel (the “Company”) and traded on Tel Aviv Stock Exchange Ltd.
(the “TASE”) and on the OTCQB; and each of the investors specified and detailed in Annex A which
has placed his signature beside his name and has executed this Agreement (each, an “Investor”; together, the
"Investors"). The term Investors in this Agreement shall refer to each of the Investors, severally and not jointly,
and without any joint responsibility among them, each according to his investment amount set forth next to his name in Annex
A. The Company and each of the Investors is referred to collectively as the “Parties” and each separately
as a “Party”.

 

WITNESSETH

 

WHEREAS,
the Company has decided to raise additional capital for the Company by means of a private placement; and

 

WHEREAS,
each Investor desires to invest its Investment Amount (as defined below) in the Company, on the terms and conditions set forth
herein;

 

NOW,
THEREFORE,
in consideration of the mutual promises and covenants set forth herein, the Parties hereby agree as follows:

 

		1.	The
                                         Transaction

 

		1.1.	The
                                         Company has decided to raise funds by offering the Offered Securities (as this term is
                                         defined below) to each of the Investors by means of a private placement against the Investment
                                         Amounts (as this term is defined below), all as further detailed in this Agreement and
                                         as specified in Annex A.

 

		1.2.	At
                                         the Execution Date, each Investor shall deposit its Investment Amount to an escrow bank
                                         account in the name of Horn Trustees Ltd. or any other trustee and bank account to be
                                         designated by the Company ("Escrow Agent" and "Escrow Account",
                                         respectively). At the Closing (as defined below) the Escrow agent shall transfer the
                                         Investment Amount to the Company. Each Investor will sign an Escrow Agent agreement,
                                         in the form attached as Annex D to the Agreement.

 

		1.3.	The
                                         offer of the Offered Securities to each of the Investors shall take place according to
                                         the terms and conditions under this Agreement and shall be in force until no later than
                                         15th day of February, 2017 (inclusive) (the "Final Investment Date"),
                                         after which the Company shall have no obligation to offer to any of the Investors any
                                         of the Offered Securities under this Agreement, or at all and the Investors will have
                                         no obligation to purchase any of the Offered Securities under this Agreement or any other
                                         obligation under this Agreement (and in this case, the Escrow Agent shall return each
                                         of the Investment Amounts deposited in the Escrow Account to their respective Investors).

 

		1.4.	The
                                         Company undertakes no obligation to complete the Transaction under this Agreement until
                                         the end of the Final Investment Date (or before), and the Company may at any time until
                                         the Final Investment Date to notify the cancellation of the transaction under this Agreement,
                                         in its sole discretion (including for no reason).

 

     

     

    

 

Execution
Copy

 

		1.5.	For
                                         the sake of good order, the Company does not limit the total investments sums under this
                                         Agreement, and shall have full discretion on deciding the total investment sum to be
                                         raised under this Agreement and each of the Investors shall have no claim and / or demand
                                         against the Company in connection therewith.

 

		2.	Issue
                                         and Purchase of Purchased Shares 

 

		2.1.	Issue
                                         and Purchase of Purchased Shares. Subject to the terms and conditions hereof, at
                                         the Closing (as defined below), the Company shall issue and sell to each Investor, and
                                         each Investor shall purchase from the Company, an amount of ordinary shares of the Company
                                         of par value NIS 0.1 each (the "Ordinary Shares") (all Ordinary Shares
                                         purchased by the Investors the "Purchased Shares" and all Ordinary Shares
                                         offered to the Investors "Offered Securities"), set forth across from
                                         its name under the caption “Offered Shares” in Annex A, free and clear
                                         of any and all Encumbrances (as defined below) at a price equal to NIS 0.70 per Purchased
                                         Share (the "Purchase PPS"), for a consideration in NIS set forth across
                                         from its name under the caption “Investment Amount” in Annex A (the
                                         “Investment Amount”). The Purchased Shares shall be transferred to
                                         the Investor's account and the Investment Amount shall be transferred to the Company's
                                         account, as set forth in Article 3 (Closing) below.

 

		2.2.	Anti
                                         Dilution Protection; Pre-Emptive Rights.

 

		2.2.1.	Anti
                                         Dilution Protection. In case after the Closing of this Agreement the Company raises
                                         additional funds by means of private placements (I.e., excluding public offerings) in
                                         less favorable terms than prescribed under this Agreement - in terms of the price per
                                         share of the Company’s ordinary shares (“Future Private Placements”
                                         and “Future PPS”, respectively), then immediately prior to the closing
                                         of such Future Private Placement the Investor (under this Agreement) shall be granted
                                         free of charge (subject to any regulatory approvals required to be obtained by the Company)
                                         such additional amount of Ordinary Shares to reflect the Difference (as defined below)
                                         that the Investor would have been offered in consideration of his Investment Amount (under
                                         this Agreement) should the Purchase PPS would have been replaced with the Future PPS.

 

The
“Difference” shall be calculated and adjusted according to a standard weighted average mechanism for each
such Future Private Placement.

 

The
Company's share capital consists and shall consist (for as long as this section 2.2 is in force) only of Ordinary Shares of the
same par value as the shares issued to the Investor hereunder all bearing equal rights.

 

		2.2.2.	Pre-Emptive
                                         Rights. In addition, the Investor will be entitled, at his option (without undertaking
                                         an obligation), to participate in any Future Private Placements at equal terms offered
                                         to other future investors, so as to maintain his percentage holding in the issued and
                                         outstanding share capital of the Company.

 

    	 	2	 

     

    

 

Execution
Copy

 

The
Company's share capital consists and shall consist (for as long as this section 2.2 is in force) only of Ordinary Shares of the
same par value as the shares issued to the Investor hereunder all bearing equal rights.

 

For
the purposes of this section, and the avoidance of doubt, the term Future Private Placements shall refer only to cash investments
(PIPEs), and shall not refer to issuance of Company’s securities (shares, options, debt, and/or any other convertible
note) not issued pursuant to cash-investment in Company’s equity. For example, and without derogating the generality of
the aforementioned, the term Future Private Placements shall not refer to any issuance made pursuant to payments due under
contractual commitment or instead of cash/debt payment, such as (not an inclusive list) achieving development or commercial milestone
under license agreement, consideration payment to service provider / contractor, settlement of indemnification debt and/or ESOP
grants.

 

The
provisions of this section 2.2 shall be in force only until the earlier between: (a) immediately prior to the consummation of
a Qualified IPO (as defined below); and (b) twelve (12) months as of the Execution Date (“ADP Duration”), following
which the provisions of this section shall become void and null. The provisions of this section 2.2 can be exercised only within
the above prescribed period (the ADP Duration) in each case of such diluting event.

 

A
“Qualified IPO” means any public offering of the equity of the Company covering the registration and/or offer
and sale of equity of the Company pursuant to which the Company’s equity interests will be quoted on the NASDAQ National
Market or other regulated securities exchange.

 

For
the sake of clarity, for purposes of this Agreement and subject to the changes required, any ordinary shares issued pursuant to
the provisions of this section 2.2 shall be considered, mutatis mutandis, as part of the Offered Securities (including, without
limitation, for the purposes of sections 5, 7.1, 9, 10 and 11 below).

 

		2.3.	Use
                                         of Proceeds. Upon the issuance of the Offered Securities to the Investor and receiving
                                         the total Investment Amount from the Investor, the Company shall use the Investment Amount
                                         according to its needs, at the discretion of the Board of Directors from time to time.

 

		2.4.	Conditions
                                         to Closing. The Closing of the transactions contemplated hereby shall be subject
                                         to the conditions set forth in Article 7 (Conditions to Closing) herein.

 

		3.	Closing

 

		3.1.	Date
                                         and Venue of Closing. The payment by the Investors of the Investment Amounts to the
                                         Company and the issuance of the Purchased Shares to the Investors (to be held by the
                                         Nominee Company, as defined below) shall take place at a closing (the “Closing”),
                                         to be held at the offices of Horn & Co. - Law Offices, Amot Investments Tower, 24th
                                         Floor, 2 Weizmann St., Tel-Aviv 6423902, Israel, within three (3) business days following
                                         the fulfillment or waiver (by the Party entitled to do so) of each of the conditions
                                         set forth herein, but no later than forty-five (45) days following the date hereof, at
                                         11:00 a.m., Israel time, or at such other time or place as the Parties shall mutually
                                         agree.

 

    	 	3	 

     

    

 

Execution
Copy

 

		3.2.	Transactions
                                         at Closing. At the Closing, the following transactions shall take place, which transactions
                                         shall be deemed to take place simultaneously and no transaction shall be deemed to have
                                         been completed or any document delivered until all such transactions have been completed
                                         and all required documents delivered:

 

		3.2.1.	the
                                         Company shall provide the Investor with:

 

		(a)	A
                                         copy of a signed share certificate issued by the Company in the name of the Nominee Company
                                         of the Company (Mizrahi-Tefahot Nominees Company Ltd.) (the "Nominee Company")
                                         for the benefit of the Investor, evidencing the ownership of the Investor of the Purchased
                                         Shares.

 

		(b)	TASE's
                                         approval of the registration for trade of the Purchased Shares.

 

		(c)	A
                                         copy of the immediate report filed by the Company on the TASE's Corporate Actions System
                                         (MAYA) and the ISA's "Magna" Site, announcing the issuance of the Purchased
                                         Shares.

 

		(d)	A
                                         true and correct copy of the Company's shareholder register, immediately after the Closing,
                                         as published by the Company.

 

		(e)	A
                                         copy of a letter of instructions, stamped as accepted (stamped “received”)
                                         by the Nominee Company, instructing the Nominee Company to deposit the Investor’s
                                         Purchased Shares underlying the share certificate in a specific bank account held by
                                         the Investor and in the Investor's name. This letter of instructions shall evidence the
                                         Investor’s ownership of the Purchased Shares.

 

		3.2.2.	The
                                         Investor shall provide the Company with:

 

		(a)	A
                                         copy of the executed written instructions to the Investor’s bank, (or the Escrow
                                         Agent, as the case may be) to transfer the Investment Amount to the Company bank account.

 

		(b)	A
                                         SWIFT letter of instructions instructing the Company to deposit the Purchased Shares
                                         in a specific bank account held by the Investor.

 

		4.	Representations
                                         and Warranties of the Company

 

The
Company hereby represents and warrants to the Investor, and acknowledges that the Investor is entering into this Agreement in
reliance thereon, as of the date hereof and as of the Closing Date (except to the extent such representation and warranty is made
only as of a specific date, in which event such representation and warranty is made as of such specific date) as follows:

 

		4.1.	The
                                         Company has all necessary power and authority to execute and deliver this Agreement and
                                         to carry out its provisions, and has obtained the approval of the Company's organs required
                                         under the applicable law for the performance of this Agreement and the transactions contemplated
                                         hereby. All action on the Company’s part required for the execution and delivery
                                         of this Agreement has been taken. Upon the execution and delivery, this Agreement will
                                         be valid and binding obligations of the Company, enforceable in accordance with its respective
                                         terms. The signatories of this Agreement on behalf of the Company are authorized to sign
                                         on its behalf.

 

    	 	4	 

     

    

 

Execution
Copy

 

		4.2.	To
                                         the best of the Company's knowledge, the Company's statements and information contained
                                         in the reports submitted by the Company to the ISA, including all periodic and immediate
                                         reports and its financial statements (the "ISA Filings") are true and
                                         accurate to the date it was filed (information received from third parties and included
                                         in the ISA Filings is true and accurate, to the Company's best knowledge), and subject
                                         to information included under the ISA Filings, since the the filing of the Company’s
                                         financial statements for the third quarter of 2016 and until the Execution Date, there
                                         have been no event or occurrence that has or is likely to have a material adverse effect
                                         on the Company.

 

		4.3.	As
                                         of the Execution Date the registered and the issued and outstanding share capital of
                                         the Company, and details regarding options, warrants, other convertible securities or
                                         other rights, issued by the Company, is as specified in ISA Filing dated January 5, 2017
                                         (T-087) and the issued and outstanding share capital of the Company held by its Interested
                                         Parties, is as specified in ISA Filing dated January 5, 2017 (T-077).

 

		4.4.	As
                                         of the Execution Date (I.e., pre Investment/Closing) the Offered Securities constitute
                                         13.07% of the issued and outstanding share capital, and 11.81% of the issued and outstanding
                                         share capital on a fully diluted basis.

 

		4.5.	The
                                         Purchased Shares of each of the Investors, when issued, sold and delivered by the Company
                                         in accordance with the terms of this Agreement for the consideration expressed herein,
                                         will be, upon issuance, listed for trading on the TASE, duly and validly authorized and
                                         issued, fully paid and non-assessable, and issued in compliance with all applicable laws,
                                         including the Israeli Securities Law, 5728-1968 and the rules and regulations promulgated
                                         thereunder from time to time (the "Securities Law") and will be free
                                         of any security interest, liability, limitation, liens, pledges, hypothecations, restrictive
                                         covenant, claims, restrictions, charge, mortgage or any other similar rights or any other
                                         third party rights, limitations or restrictions, and rights limitations or restrictions
                                         which may impose restrictions on the transfer thereof at any time (collectively "Encumbrances"),
                                         except for restrictions on transfers imposed under Section 15C of the Securities Law,
                                         as prescribed in Article 10 (Restrictions on Resale of Securities) of this Agreement
                                         below.

 

		4.6.	The
                                         Purchased Shares will have the rights, preferences and privileges set forth in this Agreement
                                         and the Articles of Association of the Company identical to the Ordinary Shares of the
                                         Company, and shall be duly registered in the names of the Investors or in the name of
                                         the Nominee Company in the Company's Shareholders Register, in favor of the Investors,
                                         and will be duly registered for trade on the TASE.

 

		4.7.	The
                                         Ordinary Shares are listed on the TASE, and the Company is in compliance with its listing
                                         requirements thereon and with all legal requirements under any applicable law, including
                                         but not limited to, the Securities Laws or the TASE’s rules. To the best of the
                                         Company's knowledge, no action has been taken or threatened by the Israeli Security Authority
                                         ("ISA"), the TASE or the OTCQB with respect to the delisting or suspension
                                         from trading of the Ordinary Shares or the American Depository Receipts traded on the
                                         OTCQB. The Purchased Shares issued to the Investor hereunder will be listed for trading
                                         on TASE immediately upon the issuance thereof to Investor subject to the rules and regulations
                                         issued by TASE, and will be freely transferable and tradable by the holders thereof on
                                         the TASE, subject to the lock-up restrictions described in Article 10 (Restrictions on
                                         Resale of Securities) below.

 

    	 	5	 

     

    

 

Execution
Copy

 

		4.8.	The
                                         Company has not paid, become or will become obligated to pay any fee or commission to
                                         any broker, finder, investment banker or other intermediary in connection with this Agreement.

 

		5.	Representations
                                         and Warranties by each of the Investors

 

Each Investor hereby represents
and warrants as of the date hereof and as of the date of the Closing, that the following representations and warranties are true
and accurate in all respects, and further acknowledges that the Company is entering into this Agreement in reliance thereon:

 

		5.1.	The
                                         Investor has all necessary power and authority to execute and deliver this Agreement
                                         and to carry out its provisions, and has obtained the approval of the Investor's organs
                                         required under the applicable law for the performance of this Agreement and the transactions
                                         contemplated hereby. All action on Investor’s part required for the execution and
                                         delivery of this Agreement has been taken. Upon the execution and delivery, this Agreement
                                         will be valid and binding obligations of Investor, enforceable in accordance with its
                                         respective terms. The signatories of this Agreement on behalf of the Investor are authorized
                                         to sign on its behalf.

 

		5.2.	The
                                         Investor acknowledges and agrees that subject to the accuracy and completeness of the
                                         representations or warranties of the Company stated in Article 4 (Company's Representations)
                                         above, it is purchasing the Offered Securities "As-Is", without any additional
                                         representations or warranties of the Company other than as stated in Article 4 above.

 

		5.3.	Investor
                                         is not a US Person, as this term is defined under the US Securities Act.

 

		5.4.	The
                                         Investor is aware that the Purchased Shares are not issued pursuant to a prospectus or
                                         similar document and that at the Closing, the Purchased Shares will be subject to restrictions
                                         on resale of securities in accordance with applicable Israeli laws and regulations (including
                                         without limitation, Section 15c of the Securities Law) as described in Article 10 (Restrictions
                                         on Resale of Securities) below. In addition, the issuance of the Purchased Shares shall
                                         be subject to any provision, limitation or approvals required by the applicable law,
                                         including without limitation by the TASE and/or the ISA, as may be the case.

 

		5.5.	The
                                         Investor has experience as an investor in securities of companies in the early and development
                                         stages and acknowledges that it can bear the economic risk of its investment, and has
                                         such knowledge and experience in financial or business matters that it is capable of
                                         evaluating the merits and risks of the investment in the Company. The Investor has experience
                                         in investing in companies similar to the Company and is capable of evaluating the risks
                                         and merits of its investment in the Company and is able bear the financial risks thereof.

 

		5.6.	Investor
                                         has the financial ability at the Execution Date and at the Closing to execute its obligations
                                         under this Agreement, including paying the Company the Investment Amount.

 

		5.7.	Except
                                         for the Offered Securities and any attached rights to such securities, the Investor will
                                         not be entitled to any other consideration and/or right from the Company other than set
                                         forth in this Agreement and the Articles of Association of the Company.

 

    	 	6	 

     

    

 

Execution
Copy

 

		5.8.	The
                                         Investor is purchasing the Purchased Shares for the Investor’s own account, not
                                         as a nominee or agent and without any present intention to resell or distribute such
                                         Purchased Shares.

 

		5.9.	Investor
                                         does not own, hold or possess, directly or indirectly, any securities of the Company.

 

		5.10.	There
                                         is no obligation, agreement and/or understanding in connection with the Offered Securities,
                                         and no agreements, whether written or oral, between the Investors themselves, and/or
                                         between any Investor and any of the Company's shareholders or any third party regarding
                                         the purchase or sale of securities of the Company or voting rights in the Company.

 

		5.11.	The
                                         Investor considered the tax implications of the transaction under this Agreement that
                                         apply to it, and the Company has not represented any representation in that respect;
                                         Subject to Article 9 (Tax) of this Agreement, should there be any tax charge imposed
                                         on the Investor in respect of or due to the allocation of the Offered Securities, the
                                         Investor shall alone bear it and be responsible to settle and pay it, and the Company
                                         assumes no liability in connection with said charge.

 

		5.12.	The
                                         Company may offer its securities to other investors and third parties under same or different
                                         terms and conditions to those set under this Agreement, and that this agreement does
                                         not prevent the Company at any time, presently or in the future to negotiate the terms
                                         of and/or to offer any of its securities and/or to raise additional funds in any way.

 

		5.13.	The
                                         Investor is not an employee or officer of the company, and will not hold or have an interest
                                         in the Company of or more than 5% of the Company's outstanding and issued shares prior
                                         to the Closing.

 

		5.14.	The
                                         Investor will cooperate with the Company and shall provide identifying information relating
                                         to the Investor (including its end-controlling entities), to the extent required by the
                                         applicable law in connection with the allocation of the Offered Securities under this
                                         Agreement.

 

		5.15.	The
                                         Investor confirms and acknowledges that subject to Closing and immediately afterwards,
                                         in case the Investor becomes an "Interested Party" in the Company, he will
                                         be subject to certain obligations and duties under the law and he undertake to fully
                                         comply with such duties and obligation.

 

		5.16.	Notwithstanding
                                         anything to the contrary herein, Investor hereby confirms and acknowledges that subject
                                         to Closing and immediately afterwards, following any issuance of Company’s securities
                                         to the Investor (including with respect to the provisions under section 2.2 above, to
                                         the extent applicable), he might be subject to Tender Offer regulations, as prescribed
                                         under the Companies Law and regulations promulgated thereof, and hereby agrees to abide
                                         and comply with such rules and regulations, as applicable.

 

		6.	Interim
                                         Covenants.

 

		6.1.	From
                                         the Execution Date and until consummation of the Closing the Company shall (a) continue
                                         to operate its business in the ordinary course consistent with past practices; (b) promptly
                                         advise the Investors of any change, event or circumstance which has, or could reasonably
                                         be expected to have a material adverse effect on the Company; (c) not declare, effectuate
                                         and/or distribute any dividends (whether in cash or in kind) or purchase any of its Ordinary
                                         Shares; (d) not undergo or be a party to any merger, consolidation or similar transaction
                                         with any person; (e) not issue any securities other than (i) Ordinary Shares in case
                                         of an exercise of outstanding options or (ii) securities in connection with transactions
                                         reported to the ISA and TASE prior to the Execution Date; (f) not amend its Articles
                                         of Association in a way which contradicts or otherwise effect the terms and conditions
                                         of this Agreement.

 

    	 	7	 

     

    

 

Execution
Copy

 

		6.2.	The
                                         Company shall promptly notify the Investors of any change, event or condition that would
                                         cause any of the representations and warranties of the Company contained in this Agreement
                                         or other document delivered pursuant hereto to be inaccurate.

 

		7.	Conditions
                                         to Closing

 

		7.1.	General
                                         Conditions. The respective obligations of each Party to consummate the transactions
                                         contemplated herein shall be subject to the fulfillment, at or prior to the Closing,
                                         of each of the following conditions, any of which may, to the extent permitted by applicable
                                         law, be waived in writing by any Party in its sole discretion (provided that such waiver
                                         shall only be effective as to the obligations of such Party):

 

		7.1.1.	No
                                         action shall have been taken, or any statute, rule, regulation or order shall have been
                                         enacted or deemed applicable to the transactions contemplated hereunder, and no temporary
                                         or permanent restraining order or preliminary or permanent injunction or other order
                                         shall have been issued by, any governmental authority, that would restrain or prohibit
                                         the consummation of the transactions contemplated by this Agreement.

 

		7.1.2.	All
                                         consents and approvals of any governmental authority required with respect to the transactions
                                         contemplated hereunder have been obtained.

 

		7.1.3.	TASE's
                                         approval and authorization for the listing of the Purchased Shares for trading on the
                                         TASE has been obtained, and in addition, to the extent required, the ISA approval for
                                         the performance of this Agreement and the transactions contemplated hereby (if at all).

 

		7.2.	Additional
                                         Conditions to Obligations of each of the Investors. The obligations of each of the
                                         Investor to consummate the transactions contemplated hereunder shall be subject to the
                                         fulfillment, at or prior to the Closing, of each of the following conditions, any of
                                         which may be waived in writing by the Investor in its sole discretion:

 

		7.2.1.	The
                                         representations and warranties of the Company contained in this Agreement or other document
                                         delivered pursuant hereto shall be true and correct both when made and as of the Closing,
                                         or in the case of representations and warranties that are made as of a specified date,
                                         such representations and warranties shall be true and correct as of such specified date.

 

		7.2.2.	At
                                         the Closing, all the Purchased Shares shall be free and clear of any Encumbrances.

 

    	 	8	 

     

    

 

Execution
Copy

 

		7.2.3.	Since
                                         the Execution Date, there shall have been no event or occurrence that has or is likely
                                         to have a material adverse effect on the Company.

 

		7.2.4.	The
                                         Company shall have performed all obligations and agreements and shall have complied with
                                         all covenants and conditions required by this Agreement to be performed prior to or at
                                         the Closing.

 

		7.2.5.	There
                                         shall have been no lawsuit, filed or threatened, which challenges this Agreement and
                                         all transactions contemplated hereby, or seeks to impose any limitation on Investor's
                                         purchase of the Purchased Shares.

 

		7.3.	Additional
                                         Conditions to Obligations of the Company. The obligations of the Company to consummate
                                         the transactions contemplated hereunder shall be subject to the fulfillment, at or prior
                                         to the Closing, of the following condition, which may be waived in writing by the Company
                                         in its sole discretion:

 

		7.3.1.	The
                                         representations and warranties of each of the Investors contained in this Agreement shall
                                         be true and correct both when made and as of the Closing, or in the case of representations
                                         and warranties that are made as of a specified date, such representations and warranties
                                         shall be true and correct as of such specified date.

 

		7.3.2.	Each
                                         of the Investors shall have performed all material obligations and agreements and shall
                                         have materially complied with all covenants and conditions required by this Agreement
                                         to be performed prior to or at the Closing.

 

		8.	Termination

 

		8.1.	Events
                                         of Termination. This Agreement may be terminated and the transactions contemplated
                                         hereby abandoned at any time prior to the Closing, by the written consent of all Parties.
                                         If the execution of this agreement has not occurred by the Final Investment Date then
                                         this Agreement shall terminate and no Party hereto shall have any rights or obligations
                                         hereunder.

 

		8.2.	Effect
                                         of Termination. In the event of termination of this Agreement as provided in this
                                         Article 8, this Agreement shall forthwith become void and there shall be no liability
                                         on the part of any Party except that nothing herein shall relieve any Party from liability
                                         for any breach of this Agreement or any agreement made as of the date hereof or subsequent
                                         thereto pursuant to this Agreement.

 

		9.	Tax
and Expenses

 

		9.1.	The
                                         Company shall bear all tax payments and charges applicable to it under the provisions
                                         of any applicable law for the sale and / or allocation of the Offered Securities, including
                                         any costs required to obtain the approval of issuance of the Offered Securities to the
                                         Investor, including but not limited to the approval of the TASE.

 

		9.2.	Each
                                         of the Investors will bear all tax payments and charges applicable to it under the provisions
                                         of any applicable law in respect of the acquisition of the Offered Securities allocated
                                         to it.

 

    	 	9	 

     

    

 

Execution
Copy

 

		9.3.	All
                                         payments to be made hereunder shall be made after deducting any withholding tax that
                                         may be due to the Israel Tax Authority (“ITA”) on account thereof
                                         at the maximum rate required by applicable law and paying over such withholding taxes
                                         to the ITA, if required; provided, that the payor shall promptly provide to payee, with
                                         respect to all amounts withheld and paid over on account of withholding taxes, a written
                                         confirmation, in a form reasonably satisfactory to the payee, that such amounts were
                                         withheld and paid over on payee’s behalf to the ITA. Notwithstanding the preceding
                                         sentence, if a payee provides the payor at any time prior to such payment with a certificate
                                         of exemption from tax withholding (or a certificate of reduced tax withholding) from
                                         the ITA, in a form reasonably satisfactory to the payor, the payee shall act in accordance
                                         with the certificate of exemption from tax withholding (or the certificate of reduced
                                         tax withholding). Any amount withheld and paid over to the ITA pursuant to this paragraph
                                         shall be deemed paid to the payee hereunder.

 

		9.4.	Each
                                         Party shall pay its own fees and expenses incurred in connection with the transactions
                                         contemplated hereby.

 

		10.	Restrictions
                                         on Resale of the Offered Securities

 

		10.1.	The
                                         Investor shall be bound to the restrictions on the resale of the Offered Securities on
                                         TASE pursuant to the provisions of Section 15C of the Securities Law and the Securities
                                         Regulations (Details Regarding Sections 15A to 15C of the Law), 2000, as amended, according
                                         to which:

 

		10.1.1.	The
                                         Investor shall be forbidden from offering for sale each and any of the Offered Securities,
                                         in the course of trading on the TASE, for a period of six (6) months from the Closing
                                         (the date on which the Offered Securities were initially issued) (the "Total
                                         Lock-up Period").

 

		10.1.2.	For
                                         a period of six consecutive calendar quarters as of the end of the Total Lock-up Period
                                         each Investor may offer for sale (in the course of trading on the TASE), on every trading
                                         day, the amount of the Purchased Shares not exceeding the average daily trading volume
                                         in the Company's shares on TASE during the period of eight (8) weeks immediately preceding
                                         the Closing, provided that such Investor does not offer in any given calendar quarter
                                         such number of Purchased Shares in excess of one percent (1%) of the issued and outstanding
                                         share capital of the Company (regardless of any convertible securities not yet exercised
                                         or converted into Ordinary Shares and allocated to the date of Closing).

 

A
"quarter" for the purposes of this section means a period of three calendar months; The beginning of the first
quarter shall commence at the end of the Total Lock-up Period.

 

		10.2.	The
                                         Investor undertakes to act in accordance with the provisions of the Securities Law, with
                                         respect to restrictions on resale of the Purchased Shares issued under this Agreement.

 

		11.	Miscellaneous

 

		11.1.	Further
                                         Assurances. Each of the Parties shall perform such further acts and execute such
                                         further documents as may reasonably be necessary to carry out and give full effect to
                                         the provisions of this Agreement and the intentions of the Parties as reflected thereby.
                                         Without derogating from the generality of the above, the Company shall request the TASE's
                                         approval of the registration for trade of the Purchased Shares within three (3) business
                                         days of the Execution Date.

 

    	 	10	 

     

    

 

Execution
Copy

 

		11.2.	Governing
                                         Law; Jurisdiction. This Agreement shall be governed by and construed according to
                                         the laws of the State of Israel, without its conflicts of choice of law provisions which
                                         would cause the application of the law of any other jurisdiction. Any dispute or other
                                         matter arising under or in relation to this Agreement shall be resolved by the competent
                                         court of the city of Tel-Aviv-Jaffa and each of the Parties hereby irrevocably submits
                                         to the exclusive jurisdiction of such court.

 

		11.3.	Successors
                                         and Assigns; Assignment. Except as otherwise expressly limited herein, the provisions
                                         hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs,
                                         executors, and administrators of the Parties. None of the Parties may assign or delegate
                                         this Agreement or any rights or obligations hereunder to any person without the prior
                                         written consent of the other Parties, which consent not be unreasonably withheld, and
                                         provided, that the Investor may assign this Agreement in whole or in part to any Affiliate
                                         of the Investor. For the purposes of this Article ‎11.3, the term “Affiliate”
                                         shall mean any person who is a Relative of the Investor, or entity that directly or indirectly
                                         Controls, is Controlled by or is under common Control with the Investor. The term “Control”
                                         shall mean the holding of at least 50% of the outstanding equity shares in, 50% of the
                                         voting power or the power to appoint at least 50% of the members of the board of directors
                                         (or other similar corporate organ) of the applicable entity. The term Relative shall
                                         mean a spouse or a descendent of the Investor, or a trustee for the same.

 

		11.4.	No
                                         Public Statements. Subject to Article 12 (Confidentiality) below, no Party hereto
                                         shall publicize or disclose the existence or the terms and conditions of this Agreement,
                                         without the express, prior written consent of the other Party, provided however, that
                                         each Party may disclose the existence of this Agreement to (1) its advisors and (2) any
                                         potential investors under a confidentiality agreement.

 

		11.5.	No
                                         Third Party Beneficiaries. Nothing in this Agreement, express or implied, is intended
                                         to or shall confer upon any other person, who is not a Party hereto, any rights, benefits
                                         or remedies of any nature whatsoever under or by reason of this Agreement.

 

		11.6.	Entire
                                         Agreement; Amendment and Waiver. This Agreement, together with the schedules and
                                         exhibits attached hereto, constitutes the full and entire understanding, arrangement
                                         and agreement between the Parties with regard to the subject matters hereof and thereof
                                         and terminate and replace any previous understanding, agreement and/or arrangement between
                                         the Parties relating thereto. Except as otherwise explicitly provided for herein, any
                                         term of this Agreement may be amended and the observance of any term hereof may be waived
                                         (either prospectively or retroactively and either generally or in a particular instance)
                                         only with the written consent of all of the Parties.

 

		11.7.	Delays
                                         or Omissions. No delay or omission to exercise any right, power, or remedy accruing
                                         to any Party upon any breach or default under this Agreement, shall be deemed a waiver
                                         of such breach or default or any other breach or default theretofore or thereafter occurring.
                                         Any waiver, permit, consent, or approval of any kind or character on the part of any
                                         Party of any breach or default under this Agreement, or any waiver on the part of any
                                         Party of any provision or condition of this Agreement, must be in writing, signed by
                                         such Party, and shall be effective only to the extent specifically set forth in such
                                         writing. All remedies, either under this Agreement or by law or otherwise afforded to
                                         any of the Parties, shall be cumulative and not alternative.

 

    	 	11	 

     

    

 

Execution
Copy

 

		11.8.	Severability.
                                         If any provision of this Agreement is held by a court of competent jurisdiction to be
                                         unenforceable under applicable law, then such provision shall be excluded from this Agreement
                                         and the remainder of this Agreement shall be interpreted as if such provision were so
                                         excluded and shall be enforceable in accordance with its terms; provided, however, that
                                         in such event this Agreement shall be interpreted so as to give effect, to the greatest
                                         extent consistent with and permitted by applicable law, to the meaning and intention
                                         of the excluded provision as determined by such court of competent jurisdiction.

 

		11.9.	Notices.
                                         All notices required or permitted hereunder shall be in writing and shall be deemed effectively
                                         given: (a) upon personal delivery to the Party to be notified; (b) when sent by facsimile
                                         or by email with confirmation of transmission, if sent during normal business hours of
                                         the recipient, if not, then on the next business day; or (c) five days after having been
                                         sent by registered or certified mail, return receipt requested, postage prepaid. All
                                         notices shall be sent to the address of such Party set forth in Annex B
                                         attached hereto or at such other address as any Party may designate by ten (10) days
                                         advance written notice to the other Parties.

 

		11.10.	Counterparts.
                                         This Agreement may be executed in any number of counterparts, each of which shall be
                                         deemed an original and all of which together shall constitute one and the same instrument.

 

		12.	Confidentiality

 

		12.1.	The
                                         Investor shall not issue a press release or public announcement concerning this Agreement
                                         or the transactions set forth therein (the "Disclosure") without the
                                         prior written consent of the Company, which approval is not to be prevented or delayed
                                         unreasonably, unless the Disclosure is required under the applicable law, in which case
                                         the Investor shall disclose said Disclosure (and all related and relevant information)
                                         to the Company, including the text of the Disclosure, sufficient time prior to the publication
                                         of the Disclosure in order to allow the Company to comment and to approve said Disclosure
                                         prior to any such publication.

 

		12.2.	The
                                         Investor acknowledges and declares that it is aware that the Company is a public company
                                         whose shares are traded on TASE and that : (1) any information about a transaction which
                                         is the subject of this Agreement may be considered as 'inside information' in accordance
                                         with the Israeli law and/or other applicable law, and shall not be used and/or exploited
                                         in any way or purpose other than for the execution of this Agreement; and (2) the Company
                                         may be required to disclose the terms of this Agreement and/or its existence, including
                                         with respect to the allocation of the Offered Securities to the Investor, which will
                                         not constitute a violation of this Agreement. Any filings of the Company to the ISA in
                                         connection with this Agreement will be made in coordination with the Investor.

 

		12.3.	The
                                         Investor will sign a confidentiality agreement, in the form attached as Annex C
                                         to the Agreement.

 

    	 	12	 

     

    

 

Execution
Copy

 

IN
WITNESS WHEREOF,
the Parties have caused this Agreement to be
duly executed and delivered as of the date first above written.

 

 

 

 

 

 

[signature
page follows]

 

    	 	13	 

     

    

 

[Signature
Page to Private Placement Agreement]

 

	THE COMPANY:	 	 
	 	 	 	 
	/s/ Dr. Ascher Shmulewitz 	 	/s/ Dr. Elran Haber
	 	 	 	 
	THERAPIX BIOSCIENCES LTD.	 	 
	 	 	 	 
	By: 	Dr. Ascher Shmulewitz	 	Dr. Elran Haber
	Title: 	Chairman	 	CEO
	 	 	 	 
	THE INVESTORS:	 	 
	 	 	 	 
	/s/ Dr. Haim Amir	 	 
	[See Annex
    A]	 	 

 

    	 	14	 

     

    

 

Execution
Copy

 

Annex
A:

 

	Investor's Signature	 	Investor's Name*	 	ID/Passport number / Company's Registered Number	 	 	Offered  Securities (Ordinary Shares only)	 	 	Investment Amount (NIS)	 	 	Bank Account	 
	 	 	Dr. Haim Amir	 	 	            	 	 	 	5,357,143	 	 	 	3,750,000	 	 	 	            	 

 

Important:

 

*
The Number of Investors shall not exceed 35, including any investors which were offered securities of the Company during the last
12 month prior to the Execution Date.

 

**
In case the Investor is a corporation of any kind, please specify in addition the name and details of the controlling persons
or shareholders in the Investor. in case there is not any controlling shareholder please specify the name and details of any interested
party which holds more than 5% of the equity interest and/or of the controlling means in the corporation.

 

    	 	15	 

     

    

 

Execution
Copy

 

Annex
B

 

NOTICES

 

	Party	 	Address	 	Fax.	 	Tel.	 	E-mail
    Address	 	Contact
    Person (+Attention)	 	With
    a copy to
	Therapix BioSciences Ltd.	 	Azrieli
    Center (Square Tower) 27th Fl., Tel Aviv Israel 	 	972-3-6167056	 	972-3-6167055	 	Elran@therapixbio.com	 	Dr. Elran Haber, CEO	 	Horn & Co. - Law Offices
    
Amot Investments Tower, 2 Weizmann St., 24 Floor, 
Tel-Aviv
    6423902, Israel 
Fax: +972-3-637-8201 
Attn: Yuval
    Horn, Adv. and Roy Ribon, Adv. 
email: yhorn@hornlaw.co.il 
rribon@hornlaw.co.il
	Dr. Haim Amir	 	12 Abba Eban Avenue

    Ackerstein Tower Bldg. D
 Herzliya 4672530 Israel

    Tel: +972 (0)73 2447777 
P.O. Box 2073 Herzliya,

    4612001 Israel	 	972(54)6660-160	 	972(73)2447-748	 	arikba@essence-grp.com	 	Arik Bar, CFO	 	Eliezer Helfan, Adv. 
111
    Arlozorov St., Tel-Aviv 62098, Israel
 Tel: 972-3-6963263
 Fax:
    972-3-6963933
 E-Mail: eli.helfan@gmail.com

 

    	 	16	 

     

    

 

Execution
Copy

 

Annex
C

 

CONFIDENTIALITY
NON-DISCLOSURE AGREEMENT

 

This
Non-Disclosure Agreement (this "Agreement") is entered into this 13th day of February, 2017,
by and between Therapix Sciences Ltd. (the "Company" or "Discloser") and Dr. Haim
Amir, ("Recipient", and together with the Company, the "Parties").

 

WHEREAS,
Company owns, possesses or has developed certain business, commercial, financial and technical information relating to, inter
alia, the technology, business, intellectual property, products, product plans and financial data of the Company, its subsidiaries
and/or its affiliate companies; and

 

WHEREAS,
Company is considering in its ordinary course of business different means of fund raising, among others, by way of private placement;
and

 

WHEREAS,
Recipient wishes to evaluate a possible investment in the Company (the "Purpose") following which the Parties
shall consider entering into that certain Private Investment in Public Equity Agreement (the "PIPE Agreement");
and

 

WHEREAS,
For that Purpose Recipient wishes to receive and/or may otherwise have access to and acquire, and the Discloser is willing to
disclose to Recipient Confidential Information (as defined below);

 

NOW,
THEREFORE, the Recipient hereby agrees as follows:

 

		1.	Definition.
                                         "Confidential Information" shall mean any information and data,
                                         whether in oral, written, graphic, machine-readable form or in any other form, tangible
                                         and non-tangible, of a proprietary or confidential nature, disclosed and/or made available
                                         by Discloser or its advisors to Recipient or otherwise acquired by Recipient as a result
                                         of or in connection with this Agreement and/or the Parties' discussions (whether prior
                                         to the execution hereof or thereafter), including without limitations the PIPE Agreement
                                         and its existence.

 

Confidential
Information shall include, without limitation, proprietary, business, financial, technical, clinical, development, experimental,
formula, design, specifications, product (actual or planned and any derivatives thereof), marketing, sales, strategy, prices,
customers, operating, employees, performance, cost, know-how, research, technique and process information, records and results,
trade secrets, patents, patent applications, copyrights, ideas, improvements and inventions (whether patentable or not) and other
works of authorship, and all record bearing media containing or disclosing such information and techniques. When appropriate,
the term "Confidential Information" shall also include samples, models and prototypes, or parts thereof. The Parties'
discussions regarding the possible investment and the terms thereof shall be further deemed Confidential Information hereunder.

 

The
confidentiality obligations of this Agreement shall not apply to any information that (i) the Recipient can document is already
in the public domain through no fault of Recipient; (ii) is shown by the Recipient, by documentary evidence, to be in its possession
at the time of execution hereof and was not acquired directly or indirectly under obligations of secrecy to the other party; or
(iii) is independently developed by the Recipient without breach of this Agreement and as proven by documentary evidence.

 

    	 	17	 

     

    

 

Execution
Copy

 

Confidential
Information shall not be deemed to be in the public domain merely because any part of the Confidential Information is embodied
in general disclosure or because individual features, components or combinations thereof are now or become known to the public.
A disclosure by Recipient of Confidential Information in response to a valid order by a court or other governmental body, or as
otherwise required by law, and to such extent necessary, shall not be considered to be a breach of this Agreement, provided,
however, that Recipient shall provide Discloser with prompt prior written notice thereof to enable Discloser to seek a
protective order or otherwise prevent or contest such disclosure.

 

Recipient
specifically acknowledges and understands that Discloser is a public company traded on the Tel-Aviv Stock Exchange Ltd. Accordingly,
(a) Discloser's Confidential Information may be considered as "inside information" pursuant to Israeli securities laws
and regulations; and (ii) Discloser is required to make certain disclosures and publications under applicable laws which may include
this Agreement and/or the Parties' engagement.

 

		2.	Restrictions.
                                         All Confidential Information delivered, made available or otherwise acquired pursuant
                                         to this Agreement (a) shall not be copied, duplicated, distributed, disseminated or made
                                         available in any way or form by Recipient (or so allowed, aided or enabled by Recipient);
                                         (b) shall be maintained in confidence and in a place and manner that ensures such confidentially
                                         (which in any event shall be not less than customary industry standards), and may only
                                         be disclosed to those employees, officers and/or directors of Recipient and/or its advisors
                                         who have a need to know and who have executed an obligation of confidentiality and restriction
                                         of use similar to the terms hereof; and (c) shall not be conveyed, used or exploited
                                         by Recipient (including its employees, officers, directors and/or its advisors), directly
                                         or indirectly, for any purpose, except for the Purpose.

 

		3.	Duration.
                                         Recipient's obligations hereunder with respect to each item of Confidential Information
                                         shall be perpetual, until such time as the Confidential Information shall have become
                                         public domain through no fault of Recipient.

 

		4.	Term.
                                         This Agreement shall be effective as of the date stated above until terminated upon
                                         thirty (30) days' prior written notice, and provided, however that the
                                         provisions of Section 3 above and Sections 5-8 below shall survive the termination or
                                         expiration of this Agreement.

 

		5.	Return
                                         of Materials. Promptly following the earlier of (i) termination or expiration of
                                         this Agreement; and (ii) within seven (7) days following a written request by the Discloser
                                         at any time, Recipient will deliver to Discloser all Confidential Information and all
                                         documents or media containing any such Confidential Information and any and all copies
                                         or extracts thereof (or shall have such documentation and/or media destroyed and shall
                                         so confirm in writing, at Discloser's sole discretion).

 

		6.	Mutual
                                         Disclaimers; No Proprietary Rights. The Parties shall have no obligation to enter
                                         into any further agreement with each other. Nothing herein shall be deemed to create
                                         any principal/agent, employee-employer, joint venture or other business relationship
                                         between the Parties. It is understood and agreed that Confidential Information is provided
                                         "AS IS". No warranties, express or implied, of any kind are given by Discloser
                                         with respect to Confidential Information provided hereunder. The Parties also understand
                                         that all Confidential Information shall remain the sole property of Discloser (or its
                                         respective owner(s)), and that no patent, copyright, trademark or other proprietary right
                                         or license is granted by this Agreement. Recipient understands that nothing herein requires
                                         the disclosure of any Confidential Information, which shall be disclosed, if at all,
                                         solely at the option of the Discloser.

 

    	 	18	 

     

    

 

Execution
Copy

 

		7.	Injunctive
                                         and Other Relief; No Derogation of Rights. Since a breach by Recipient of any of
                                         the promises or agreements contained herein may result in irreparable and continuing
                                         damage to Discloser for which there may be no adequate remedy at law, Discloser shall
                                         be entitled to injunctive relief and/or a decree for specific performance, and such other
                                         relief as may be proper (including monetary damages if appropriate). Nothing in this
                                         Agreement shall be construed as derogating from any right or remedy that the Discloser
                                         may be entitled to under applicable law.

 

		8.	General.
                                         This Agreement shall bind and inure to the benefit of the Parties and their successors
                                         and assigns. Neither Party may transfer or assign any rights or obligations under this
                                         Agreement without the prior written consent of the other Party, except to a successor
                                         in interest who is not a competitor of the other Party. This Agreement represents the
                                         entire understanding and agreement between the Parties with respect to the subject matter
                                         hereof and supersedes all prior communications, agreements and understandings relating
                                         to the subject matter hereof. In the event that any of the provisions of this Agreement
                                         shall be held by a court or other tribunal of competent jurisdiction to be illegal, invalid
                                         or unenforceable, such provisions shall be limited or eliminated to the minimum extent
                                         necessary so that this Agreement shall otherwise remain in full force and effect. No
                                         modification or amendment of this Agreement will be valid unless executed by both Parties.
                                         The observance of any term hereof may be waived (either prospectively or retroactively
                                         and either generally or in a particular instance) only with the written consent of the
                                         Party against such waiver is sought and to such extent set forth therein; no failure
                                         or delay in enforcing any right will be deemed a waiver. The laws of the State of Israel
                                         shall govern this Agreement, and the competent courts of the Tel Aviv-Jaffa district
                                         shall have exclusive jurisdiction in any matter arising out of or relating to this Agreement.

 

	/s/ Dr. Ascher Shmulewitz 	 	/s/ Dr. Elran Haber
	 	 	 	 
	Therapix bioSCIENCES LTD.	 	 
	 	 	 	 
	Name: 	Dr. Ascher Shmulewitz	 	Dr. Elran Haber
	Title: 	Chairman	 	CEO
	 	 	 	 
	/s/ Dr. Haim Amir	 	 
	 	 	 
	Recipient	 	 
	 	 	 	 
	Name: 	Dr. Haim Amir	 	 

 

    	 	19	 

     

    

 

Execution
Copy

 

Annex
D

 

ESCROW
AGENT AGREEMENT

 

February
13, 2017

 

To:

Horn
Trustees Ltd. (the "Escrow Agent"),

Horn
& Co., Law Offices

2
Weizmann St., Amot Investments Tower, Fl. 24,

Tel
Aviv, 6423902, Israel

 

Dear
Sirs,

 

Reference
is hereby made to a certain Private Placement Agreement (the "Agreement") entered into as of the 13th
day of February, 2017, by and between Dr. Haim Amir ("Investor") and Therapix Biosciences
Ltd. ("Company"), pursuant to which the Investor has agreed to purchase from the Company 5,357,143
ordinary shares of the Company ("Purchased Shares") for an aggregate consideration of NIS 3,750,000 ("Investment
Amount"), subject to the terms and conditions set forth in the Agreement.

 

The
purpose of these instructions ("Escrow Instructions") is to authorise and enable the Escrow Agent to receive
the Investment Amount from the Investor and to hold such consideration in escrow pursuant to the following terms:

 

		
                                         1.	Any
                                         term not defined herein shall have the meaning given to it in the Agreement.

 

		2.	Escrow
                                         Agent will be regarded at all times solely as an escrow agent with respect to its holding
                                         of the Investment Amount and will not be considered a party to any other contractual
                                         arrangement between the Investor and the Company in connection with the Agreement.

 

		

                                                                                3.
	Upon
                                         the execution of the Agreement (at the Execution Date), the Investor will deposit the
                                         Investment Amount in an escrow account held and managed by the Escrow Agent, all in accordance
                                         with the bank wire instructions as provided by the Escrow Agent.

 

		
                                         4.	Until
                                         the Investment Amount is released by the Escrow Agent as provided herein, the Investment
                                         Amount shall be deposited in a daily, self-renewing, Shekel deposit.

 

		
                                         5.	Escrow
                                         Agent will hold the Investment Amount in escrow, to be released (together with any accrued
                                         interest and after deducting any bank transfer fees), either to Investor or the Company
                                         (as applicable) upon the earlier of:

 

		5.1	To
                                         Company - no earlier than two (2) business days after the date upon which the Company
                                         presents Escrow Agent with a copy of the Share Certificate, together with the Company's
                                         irrevocable instructions to the Nominee Company to deposit the Purchased Shares in the
                                         Investor's bank Account (as designated by the Investor), both such documents stamped
                                         "received" by the Nominee Company ("Acknowledgment of Receipt Documents").

 

		5.2	To
                                         Investor - if the Acknowledgment of Receipt Documents are not delivered to the Escrow
                                         Agent with ten (10) business days following the Closing.

 

    	 	20	 

     

    

 

Execution
Copy

 

		5.3	Release
                                         of the Investment Amount to the Investor or to the Company pursuant to the above provisions
                                         Clauses 5.1 or 5.2, is subject to a twenty-four (24) hour advance written notice by Escrow
                                         Agent to both Investor and Company.

 

		5.4	Upon
                                         the release of the Investment Amount to the Investor or to the Company pursuant to the
                                         provisions Clauses 5.1 or 5.2, Escrow Agent’s obligations hereunder will expire.

 

		5.5	Escrow
                                         Agent will not have or incur any liability whatsoever by reason of any of Escrow Agent’s
                                         acts or omissions, whether based upon mistake of fact or law, error of judgment, on the
                                         condition that the said acts or omissions are in good faith.

 

		5.6	Each
                                         of the parties, jointly and severally, and upon the Escrow Agent’s first demand,
                                         agree to indemnify fully and hold the Escrow Agent harmless against and with respect
                                         to, any and all loss, liability, damage, or expense that the Escrow Agent may suffer
                                         or incur in connection with the performance of its obligations under this Agreement or
                                         otherwise in connection therewith.

 

		5.7	The
                                         duties of the Escrow Agent are only as herein specifically provided, and are purely administrative
                                         in nature. The Escrow Agent shall neither be responsible for or under, nor chargeable
                                         with knowledge of, the terms and conditions of any other agreement, instrument or document
                                         in connection herewith except these Escrow Instructions, and shall be required to act
                                         in respect of the Investment Amount only as provided in these Escrow Instructions.

 

IN
WITNESS WHEREOF, these instructions have been executed by the parties effective as of the date indicated above.

 

	/s/
Dr. Haim Amir	 	/s/
Dr. Ascher Shmulewitz 		/s/
    Dr. Elran Haber
	Dr.
    Haim Amir	 	Therapix Biosciences Ltd.

 

Please
execute this letter below to acknowledge the terms and conditions hereof.

 

ACKNOWLEDGED
AND AGREED:

 

	 	 
	 	 
	/s/
    Yuval Horn	 
	Horn
    Trustees Ltd.	 

 

 

21Exhibit 10.15

 

Amendment
to Private Placement Agreement

 

THIS
AMENDMENT TO PRIVATE PLACEMENT AGREEMENT (the “Amendment”) is made as of February 28, 2017 by and among Therapix
Biosciences Ltd. (the “Company”) and Dr. Haim Amir (the “Investor”). The Company
and the Investor is referred to collectively as the “Parties” and each separately as a “Party”.

 

WITNESSETH

 

WHEREAS,
The Parties have each agreed on the terms of the Private Placement Agreement dated as of February 13, 2017 (the “Agreement”);
and

 

WHEREAS,
The Parties desire and agree to amend the Agreement, as set forth herein;

 

NOW,
THEREFORE, the Parties hereby agree as follows:

 

		1.	The
                                         above recitals are hereby made part of this Amendment.

 

		2.	Unless
                                         expressly provided otherwise, all capitalized terms used and not otherwise defined herein
                                         shall bear the respective meanings ascribed to them in the Agreement.

 

		3.	Section
                                         2.2.1 to the Agreement shall become section 2.2.1A and the following section 2.2.1B shall
                                         be added to the Agreement as section 2.2.1B: 

 

		2.2.1B	Protection
                                         in case of a public offering. In case after the Closing of this Agreement the Company
                                         raises additional funds by means of a Qualified IPO (as defined below) for additional
                                         capital of more than USD 1M and in less favorable terms than prescribed under this Agreement
                                         - in terms of the price per share of the Company’s ordinary shares “Future
                                         IPO” and “Future IPO PPS”, respectively), then immediately
                                         following the closing of such Future IPO, the Company shall repay the Investor the sum,
                                         reflecting the number of the Purchased Shares by the Investor multiplied by the difference
                                         between the Purchase PPS and the Future IPO PPS (the “Investment Return”).
                                         This protection shall apply to the first Qualified IPO, which will be completed in the
                                         registration of the Company’s securities on a regulated Exchange.

 

Such
Investment Return can be repaid by the Company to the Investor, at the sole discretion of the Company, either in cash and/or in
Ordinary Shares as fully paid up, at the Future IPO PPS. I.e. the number of Ordinary Shares entitled to the Investor as a repayment
under this section will be determined by dividing the Investment Return amount with the Future IPO PPS.

 

For
the avoidance of doubt, the repayment of the Investment Return by way of Ordinary Shares as aforesaid (or the Difference shares,
as the case may be) shall be subject to the obtainment by the Company of any regulatory approval required to be obtained by the
Company (including with respect to any exchange regulations and without derogating the abovementioned, including with respect
to TASE’s minimal effective price per share requirement of NIS 0.30, all as defined under TASE’s regulations as may
be from time to time).

 

		4.	Unless
                                         amended hereby, all provisions of the Agreement shall remain in full force and effect.

 

    

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized representatives as of the
date first above written.

 

 

 

 

 

[signature
page follows]

 

    

     

    

 

[Signature
Page to Amendment to Private Placement Agreement]

 

	THE
    COMPANY:	 	 
	 	 	 
	/s/
    Guy Goldin 	 	/s/ Dr. Elran
    Haber
	 	 	 	 
	THERAPIX
    BIOSCIENCES LTD.	 	 
	 	 	 	 
	By:	Guy Goldin	 	Dr. Elran
    Haber
	Title:	CFO	 	CEO
	 	 	 
	THE
    INVESTOR:	 	 
	 	 	 
	/s/
    Dr. Haim Amir	 	 
	DR.
    HAIM AMIR

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]